- Bisphosphonates in breast cancer: teaching an old dog new tricksMatthew C Winter
Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, UK to Top
Curr Opin Oncol 21:499-506. 2009..However, recent data suggest that bisphosphonate use in breast cancer may provide more than just supportive care and modify the course of the disease by disrupting the metastatic process...
- Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot studyMatthew C Winter
Academic Unit of Clinical Oncology, CR UK YCR Sheffield Cancer Research Centre, Weston Park Hospital, Sheffield, United Kingdom
Clin Cancer Res 19:2755-65. 2013..To investigate the short-term biologic effects of neoadjuvant chemotherapy +/- zoledronic acid (ZOL) in invasive breast cancer...
- Exploring the anti-tumour activity of bisphosphonates in early breast cancerM C Winter
Academic Unit of Clinical Oncology, Section for Cancer, Cancer Research Centre, University of Sheffield, Weston Park Hospital, Sheffield S10 2SJ, UK
Cancer Treat Rev 34:453-75. 2008....
- Ten years of rituximab in NHLMatthew C Winter
Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, University of Sheffield, UK
Expert Opin Drug Saf 8:223-35. 2009..Rituximab, a chimeric mouse/human monoclonal antibody targeting the pan-B-cell antigenic marker CD20, was the first monoclonal antibody licensed for use in the treatment of cancer...